Role of Hippo pathway dysregulation from gastrointestinal premalignant lesions to cancer
Giulia Schiavoni,Beatrice Messina,Stefano Scalera,Lorenzo Memeo,Cristina Colarossi,Marzia Mare,Giovanni Blandino,Gennaro Ciliberto,Giulia Bon,Marcello Maugeri-Saccà
DOI: https://doi.org/10.1186/s12967-024-05027-8
IF: 8.44
2024-02-29
Journal of Translational Medicine
Abstract:Abstract Background First identified in Drosophila melanogaster , the Hippo pathway is considered a major regulatory cascade controlling tissue homeostasis and organ development. Hippo signaling components include kinases whose activity regulates YAP and TAZ final effectors. In response to upstream stimuli, YAP and TAZ control transcriptional programs involved in cell proliferation, cytoskeletal reorganization and stemness. Main text While fine tuning of Hippo cascade components is essential for maintaining the balance between proliferative and non-proliferative signals, pathway signaling is frequently dysregulated in gastrointestinal cancers. Also, YAP/TAZ aberrant activation has been described in conditions characterized by chronic inflammation that precede cancer development, suggesting a role of Hippo effectors in triggering carcinogenesis. In this review, we summarize the architecture of the Hippo pathway and discuss the involvement of signaling cascade unbalances in premalignant lesions of the gastrointestinal tract, providing a focus on the underlying molecular mechanisms. Conclusions The biology of premalignant Hippo signaling dysregulation needs further investigation in order to elucidate the evolutionary trajectories triggering cancer inititation and develop effective early therapeutic strategies targeting the Hippo/YAP pathway.
medicine, research & experimental